# Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)

> **NCT06582628** · PHASE2 · RECRUITING · sponsor: **Fundacion Oncosur** · enrollment: 78 (estimated)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide capsule
- **DRUG:** Enzalutamide capsule and Talazoparib capsule

## Key facts

- **NCT ID:** NCT06582628
- **Lead sponsor:** Fundacion Oncosur
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-05
- **Primary completion:** 2026-01-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2024-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06582628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06582628, "Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06582628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*